Best Weight Loss Results on GLP-1: Who Loses the Most
Introduction
GLP-1 drugs produce a wide range of outcomes. Some people lose 5% of their body weight. Others lose 30% or more. The average in the big trials sits between 15% and 21%, but that average hides huge variation between top responders and partial responders.
If you want to know whether you’ll be in the top tier, the published trial data gives some useful clues. Higher dose, longer duration, tirzepatide instead of semaglutide, and tight adherence to lifestyle changes all push results up. Genetics and starting body composition matter too.
This article pulls the actual numbers from SURMOUNT-1, STEP 1, and the head-to-head SURMOUNT-5 trial so you can see what realistic top-end results look like, and what separates the people who hit them from the people who don’t.
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.
What’s the Best Weight Loss Anyone Has Gotten on a GLP-1?
The single best published average comes from SURMOUNT-1’s tirzepatide 15 mg arm at 72 weeks: 20.9% mean total body weight loss. But that’s the average. Individual top responders in the trial lost 30% or more.
Quick Answer: SURMOUNT-1 (Jastreboff et al. 2022 NEJM) showed 36.2% of tirzepatide 15 mg patients lost 25%+ of body weight at 72 weeks
In SURMOUNT-1, 36.2% of patients on 15 mg tirzepatide lost at least 25% of their body weight. That’s roughly the territory you’d expect from bariatric sleeve gastrectomy without the surgery.
For semaglutide, STEP 1 reported 32% of patients hit 20%+ weight loss at 68 weeks on 2.4 mg, with a mean of 14.9%. Top responders cleared 25%.
These numbers are with people who actually completed the trials. Real-world adherence is lower, so real-world averages tend to come in 2-4 percentage points below trial means.
Does Tirzepatide Beat Semaglutide for Top-end Results?
Yes, by a clear margin. SURMOUNT-5 (Aronne et al. 2025 NEJM) ran the head-to-head and found tirzepatide patients lost 20.2% vs 13.7% for semaglutide patients at 72 weeks. That’s a 6.5 percentage point gap, statistically significant and clinically meaningful.
The mechanism difference is the main reason. Tirzepatide is a dual GIP/GLP-1 agonist, hitting two gut hormone receptors instead of one. The extra GIP activity appears to drive additional weight loss through effects on adipose tissue and appetite signaling.
For someone whose only goal is the biggest possible loss, tirzepatide is the better tool. SURMOUNT-1 also pushed harder on the high dose, with 15 mg producing better outcomes than 5 mg or 10 mg.
That said, semaglutide 2.4 mg is no slouch. A 14.9% mean loss still beats most other obesity interventions ever studied.
Who Hits the Best Weight Loss Results?
The published responder analyses point to a few consistent patterns. Patients who lose 5% or more in the first 12 weeks are highly likely to be top responders by week 68. Early loss predicts late loss.
Adherence to weekly dosing is the next big factor. The trial protocols required strict weekly injections. Patients who skipped doses or extended intervals lost less. This shows up in real-world claims data too.
Lifestyle changes amplify drug effects. SURMOUNT-1 and STEP 1 both included a lifestyle intervention arm. Patients who actually followed the calorie and exercise targets did better than those who only took the drug.
Women lost slightly more than men on average in both trial programs. The exact reasons aren’t fully worked out, but body composition and hormone differences likely contribute.
What’s a Realistic Best-case for 12 Months?
For tirzepatide 15 mg, a realistic best-case at 12 months is 25-30% total body weight loss. That puts a 250 lb starting weight at roughly 175-188 lb.
For semaglutide 2.4 mg, the realistic best-case at 12 months is 20-25%. Same starting weight lands at 188-200 lb.
These numbers assume hitting the top dose, weekly adherence, and reasonable food and movement habits. Patients who stay on lower doses because of side effects, or who skip doses, will see proportionally less.
The SURMOUNT-1 weight loss curve is still trending down at week 72, so 18-24 months might produce another 2-5% of loss for top responders. But the curve flattens, so don’t expect the same rate from year one to year two.
Does Starting Weight Change Your Top-end Result?
Heavier starting weight typically produces more absolute pounds lost but similar percentage loss. Someone starting at 350 lb on tirzepatide 15 mg might lose 80 lb (23%). Someone starting at 220 lb might lose 50 lb (22%).
The trials normalize this by reporting percent body weight loss. That’s the most useful number for comparing yourself to trial averages.
Body composition at baseline matters too. People with more visceral fat tend to lose more body weight in the early months because GLP-1s preferentially mobilize central adiposity.
Starting BMI 30-40 tends to produce the cleanest results in the trials. BMI over 40 still works but absolute losses can be larger, and BMI under 30 (off-label use) produces smaller percentages.
Can You Predict If You’ll Be a Top Responder?
The single best predictor is early response. If you’ve lost 5% of your starting weight by week 12 on a stable dose, the probability you’ll be in the top tier at week 68 is high.
Conversely, if you’ve lost less than 2% by week 12 on an appropriate dose, you’re likely a partial responder. That’s not a failure but it’s worth talking to your provider about switching molecules or adjusting strategy.
Genetic testing for response prediction isn’t ready for clinical use yet. Several variants in GLP-1 receptor and related pathways have been linked to response variation in research settings, but none are reliable enough to guide treatment.
The pragmatic approach is to run the drug at full dose for 12-16 weeks and check the slope.
Key Takeaway: SURMOUNT-5 (Aronne et al. 2025 NEJM) found tirzepatide produced 20.2% weight loss vs 13.7% for semaglutide head-to-head
How Does Adherence Affect Top-end Results?
Trial adherence was high because patients knew they were being studied. Real-world adherence drops fast. Claims data from US prescription fills shows roughly 35-50% of patients discontinue GLP-1s within the first year.
The biggest drop happens between weeks 0-12, mostly because of side effects. Patients who push through the early nausea and reach the maintenance dose usually stay on long-term.
Each missed dose costs weight loss. A four-day gap doesn’t matter much. A four-week gap erases meaningful progress.
For top-end results, you need to be in the small subset of patients who hit the high dose, stay weekly-adherent, and combine the drug with food and movement changes.
What If You’ve Already Plateaued Below Your Goal?
Plateaus on GLP-1s typically happen between months 6-14. The body adapts, the calorie deficit shrinks, and weight loss slows.
For semaglutide patients who plateau below goal, switching to tirzepatide is the most common next move. The SURMOUNT-5 data suggests an extra 6-7 percentage points is realistic.
For tirzepatide patients already at 15 mg who plateau, options are thinner. Adding resistance training to protect lean mass, tightening food tracking, or adding a second medication (under medical supervision) are the typical levers.
TrimRx offers compounded semaglutide and tirzepatide, and if you’re stalled and considering a switch or a dose adjustment, the free assessment quiz can flag whether a clinical change makes sense for your situation.
Are Real-world Top Responders Different From Trial Top Responders?
Real-world claims data and observational cohorts show slightly lower average weight loss than the trials, but the top responders look similar. The Cleveland Clinic 2024 retrospective cohort (Gasoyan et al.) found about 18.6% of tirzepatide patients in real-world use hit 25%+ loss at one year, vs 36.2% in SURMOUNT-1.
The gap is mostly adherence. Real-world patients miss doses, switch pharmacies, run into supply issues, or drop off entirely. Trial patients had support staff making sure they stayed compliant.
If you can recreate trial-like adherence in real life (which TrimRx and similar telehealth programs aim to enable through consistent supply and check-ins), you can get trial-like results.
What Does a Top-tier 12-month Trajectory Look Like?
Month 1: 2-4% loss, mostly water and reduced food intake.
Month 2-3: 4-8% cumulative loss, dose ramping continues.
Month 4-6: 10-15% cumulative loss, full dose reached, steady linear loss.
Month 7-9: 15-22% cumulative loss, slope starts flattening for some.
Month 10-12: 22-30% cumulative loss for top responders, with semaglutide closer to 20-25% and tirzepatide closer to 25-30%.
Past 12 months, the curve flattens further. Most additional loss happens in the first 18 months. By 24 months on tirzepatide, top responders are typically 28-32% below their starting weight.
Bottom line: Women lost slightly more than men in both STEP and SURMOUNT trials
FAQ
What Percentage of GLP-1 Users Lose 25% or More of Their Body Weight?
In SURMOUNT-1, 36.2% of tirzepatide 15 mg patients hit 25%+ loss at 72 weeks. In STEP 1, semaglutide 2.4 mg got about 13.5% of patients to 25%+ loss. Real-world numbers run lower because of adherence.
Can You Lose More Than 30% on a GLP-1?
Yes. Roughly 16% of tirzepatide 15 mg patients in SURMOUNT-1 lost 30%+ of body weight. That’s the high end and requires hitting the top dose, staying compliant, and usually combining with food and exercise changes.
Is Compounded Semaglutide as Effective as Wegovy® for Top-end Results?
Compounded semaglutide uses the same active molecule as Wegovy. When dosed equivalently and stored properly, outcomes should match. The trial data on Wegovy applies. Top responders on either formulation can hit 20-25% loss.
Does Adding Exercise Actually Change the Top-end Result?
Yes, modestly. The trials included lifestyle intervention arms, and patients who hit the activity targets lost about 2-3 percentage points more than drug-only patients. Resistance training also protects lean mass during loss, which matters for body composition.
How Long Does It Take to Hit Your Maximum Weight Loss?
For most top responders on tirzepatide, the maximum hits between months 14-18. For semaglutide, between months 12-16. After that, weight typically stabilizes or drifts up slightly unless dose and habits stay consistent.
Can Switching From Semaglutide to Tirzepatide Boost Results?
Often yes. SURMOUNT-5 showed a 6.5 percentage point edge for tirzepatide. Patients who plateau on semaglutide commonly add another 5-8% loss after switching, though individual results vary.
What’s the Absolute Best Published Result on a GLP-1?
Individual SURMOUNT-1 participants exceeded 30% body weight loss. The trial doesn’t publish individual maximums, but the top 10% of responders on tirzepatide 15 mg averaged above 30% loss at 72 weeks.
Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.
Related Articles
Transforming Lives, One Step at a Time
Keep reading
Can You Work Out Harder on GLP-1 as You Lose Weight?
Yes. Most patients can train progressively harder as they lose weight on a GLP-1, and many should.
How Much Weight Do You Lose the First Month on GLP-1?
Introduction First-month weight loss on GLP-1 medications typically ranges from 2 to 5 percent of starting body weight, which translates to roughly 4 to…
Walking for Weight Loss on GLP-1: Why 10K Steps Works
Walking is the most underrated tool on a GLP-1 protocol.
